Immersive surgical training platform reaches new heights in recognition

Tern plc

Fundamental Surgery’s recent distinction as the Best Healthcare & Wellness Solution at the 2025 Auggie Awards confirms more than just cutting-edge technology, it signals a pivotal moment in the integration of virtual reality and haptic feedback into mainstream medical education. For investors, the platform’s recognition at a leading XR showcase underlines a deepening confidence in its strategic vision, technical execution and long-term scalability.

This solution combines photorealistic VR environments with advanced haptic devices, delivering an immersive learning experience that mimics the tactile nuances of real procedures. More importantly, it does so in a flexible, repeatable and globally accessible format. Surgeons and trainees can practice complex procedures anywhere, anytime, without the logistical constraints of traditional cadaver labs or proctorship. This dramatically reduces cost per trainee and offers a return on investment through standardised, measurable training outcomes.

Fundamental Surgery’s partnerships demonstrate its capacity to adapt to diverse clinical needs. Collaborations with entities such as the American Academy of Ophthalmology have enabled retinopathy of prematurity (ROP) training modules, while alliances with Orbis International support cataract surgery in resource-limited environments. These initiatives illustrate the platform’s dual appeal: rigorous enough for academic and high-end clinical settings, yet tailored for deployment in underserved regions. For investors, this suggests a unique capacity to address both high-margin developed-market demand and high-impact emergent-market opportunities.

In terms of commercialisation, recognition from the Auggie Awards provides an external validation that supports conversations with institutional buyers, hospitals, academic medical centres and ministries of health. Awards of this nature often translate into enhanced credibility, easier regulatory engagement and greater media visibility, each boosting the likelihood of enterprise contracts and public-sector procurement. From an investor perspective, that momentum can accelerate market adoption and revenue growth.

On the product front, the platform’s modular nature allows for gradual expansion into complementary surgical fields. Once a base of trained users is established in ophthalmology, the same VR/haptic architecture lends itself to orthopaedics, general surgery, neurosurgery and beyond. This blueprint supports a multi-pronged approach: deepening penetration in existing clinical verticals and broadening into adjacent specialities without reengineering the underlying platform. That strategy aligns well with sustainable revenue growth and potentially recurring subscription models.

Moreover, as global healthcare systems seek to contain costs while improving training efficacy, interest in simulation-based education is accelerating. Funders and regulators alike have recognised that digital training aspires to standardise skills assessment and reduce procedure-related complications. The Auggie Award amplifies this narrative, reinforcing investor confidence that a growing number of institutions will view this platform as a strategic imperative, not a “nice-to-have” novelty.

Underlying all this is the company’s declared mission: to democratise access to world-class surgical education. This mission resonates strongly with impact investors, development agencies and global health partnerships. The combination of high-end technology with social purpose supports a diversified funding pipeline, blending venture capital with grants, public-private collaboration and impact finance. Such a funding mix can reduce dilution, lengthen runways and bridge to commercial scale with more resilience.

Operationally, the challenge ahead lies in executing global roll-out, ensuring customer support, and scaling content development. Partnerships with education institutions and medical societies are vital to maintain validation and user-engagement. Technically, continuing investment in realism and data analytics will help position the product as a source of certification-worthy skill assessment. But the Auggie Award itself may help attract elite engineering talent and institutional interest to further close these loops.

As investors look forward, there are meaningful inflection points to consider. Near-term metrics may include adoption by major teaching hospitals, new vertical launches, revenue benchmarks and expanding content libraries. Broader validation, such as inclusion in residency curricula or formal acceptance by surgical boards, would demonstrate deeper institutional integration. And on the global stage, measurable impact in improving surgical delivery in low-resource settings would affirm both the mission and the model.

In aggregate, this recognition signals that Fundamental Surgery has built more than an immersive training tool, it has created a platform capable of systemic impact. For investors, that blend of innovation, validation and potential scale offers a rare opportunity: to support a company that is commercially robust, mission-aligned and positioned at the frontier of medical simulation.

Fundamental Surgery delivers a scalable VR and haptic simulation platform engineered to elevate surgical training across diverse settings. This award‑winning solution enhances practitioner skills, improves patient safety and unlocks new models for medical education.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search